Studies evaluating biomarkers in patients treated with ICIs in MSI cancer, with adapted REMARK criteria
| Studies | N | Biomarker | Prospective set | Control arm | Validation set | Recommendation | Ref. |
|---|---|---|---|---|---|---|---|
| Mandal, 2019 | 33 | MSI sensor | NO | NO | NO | C | [47] |
| Georgiadis, 2019 | 23 | MSI sensor | NO | NO | NO | C | [48] |
| Kawazu, 2022 | 114 | HLA-ABC | NO | YES | NO | B | [54] |
| Middha, 2019 | 13 | B2M | NO | NO | NO | C | [55] |
| Germano, 2021 | 38 | B2M | NO | NO | NO | C | [56] |
| Zhang, 2022 | 35 | B2M | NO | NO | NO | C | [57] |
| Schrock, 2019 | 22 | TMB | NO | NO | NO | C | [49] |
| Loupakis, 2020 | 80 | TMB/TILS | NO | NO | NO | C | [50] |
| Chida, 2021 | 45 | TMB | NO | NO | NO | C | [51] |
| Manca, 2023 | 110 | TMB | NO | NO | NO | C | [52] |
| Westcott, 2023 | 26 | Clonal neoantigen burden | NO | NO | NO | C | [53] |
| Quintanilha, 2023 | 320 | MSI (NGS) | NO | YES | YES | B | [46] |
| Pietrantonio, 2021 | 305 | Nomogram | NO | NO | YES | C | [60] |
| Sui, 2022 | 66 | Inflammatory signature | NO | NO | YES | C | [58] |
| Corti, 2021 | 163 | Inflammatory signature | NO | NO | NO | C | [59] |
| Saberzadeh-Ardestani, 2023 | 33 | Inflammatory signature | NO | NO | NO | C | [61] |
| Gallois, 2023 | 138 | Stromal signature | NO | NO | YES | C | [62] |
| Chida, 2022 | 36 | CMS | NO | NO | NO | C | [63] |
| Sui, 2021 | 43 | DKK1 | NO | NO | NO | C | [64] |
| Bortolomeazzi, 2021 | 29 | WNT/TMB/B2M | NO | NO | YES | C | [65] |
| Ratovomanana, 2023 | 129 | Multiplex MSI signature/TGF-β signature | NO | NO | YES | C | [71] |
ICIs: immune checkpoint inhibitors; MSI: microsatellite unstable; HLA: human leukocyte antigen; B2M: beta 2 microglobulin; TMB: tumor mutational burden; TILS: tumor infiltrating lymphocytes; NGS: next generation sequencing; CMS: consensus molecular subtype; DKK1: Dickkopf 1; TGF-β: transforming growth factor beta